JonesTrading Downgrades CymaBay Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Sean Kim downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Hold, indicating a more cautious outlook on the company's stock.
February 13, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CymaBay Therapeutics was downgraded from Buy to Hold by JonesTrading analyst Sean Kim, suggesting a neutral outlook on the stock's short-term performance.
The downgrade from Buy to Hold by a financial analyst typically indicates a shift to a more neutral stance on the stock's potential for short-term gains. This could lead to a stabilization or slight decrease in investor enthusiasm, impacting the stock's short-term price movement.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90